產品描述: | Oxamflatin (Metacept-3) is a potent HDAC inhibitor with an IC50 of 15.7 nM. |
靶點: |
HDAC:15.7 nM (IC50);HDAC |
體內研究: |
Injection of oxamflatin, six times at the dose of 20 mg/kg, exhibits a significant increase in the days of survival (38% of ILS). The ILS of the mice treated with oxamflatin at the dose of 50 mg/kg is calculated to be more than 67% and one mouse survived over 60 days after tumor inoculation. No subsidiary effect, such as body weight loss, is observed at least up to this dose |
參考文獻: |
1. Kim YB, et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 1999 Apr 15;18(15):2461-70. 2. Wang YL, et al. HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines. Curr Mol Med. 2016;16(3):232-42. 3. Faghihloo E, et al. The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line. Cancer Gene Ther. 2016 Nov;23(11):396-399. |
溶解性: |
Soluble in DMSO |
保存條件: |
2-8℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.921 ml |
14.604 ml |
29.208 ml |
5 mM |
0.584 ml |
2.921 ml |
5.842 ml |
10 mM |
0.292 ml |
1.46 ml |
2.921 ml |
50 mM |
0.058 ml |
0.292 ml |
0.584 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |